New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:24 EDTSTEMStemCells price target raised to $5.00 from $2.50 at Maxim
After reviewing StemCells' proof of concept data in an early dry-AMD trial, Maxim doubled its price target on the shares and said its new $5.00 target could still be conservative. The firm thinks dry-AMD has the potential to be a blockbuster opportunity that could be transformational for StemCells and keeps a Buy rating on the stock.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
08:13 EDTSTEMStemCells completes enrollment in first cohort of Phase II Pathway Study
StemCells announced that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of cervical spinal cord injury.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use